Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients

APMIS

Volumn 119, Issue 4-5, 2011, Pages 263-274

  Lee, Baoleri ^a,c   Schjerling, Charlotte K ^b   Kirkby, Nikolai ^b   Hoffmann, Nadine ^a   Borup, Rehannah ^b   Molin, Søren ^c   Høiby, Niels ^a,b   Ciofu, Oana ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Biofilm; Cystic fibrosis; Gene expression; Mucoidy; P. aeruginosa

Indexed keywords

ALGINIC ACID;

ARTICLE; BACTERIUM ISOLATE; BIOFILM; CHRONIC LUNG DISEASE; CYSTIC FIBROSIS; GENE CONTROL; GENE EXPRESSION PROFILING; GENOTYPE PHENOTYPE CORRELATION; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; SEQUENCE ANALYSIS; SURVIVAL TIME;

ALGINATES; BACTERIAL PROTEINS; BIOFILMS; CHRONIC DISEASE; CYSTIC FIBROSIS; DENMARK; GENE EXPRESSION PROFILING; GENES, BACTERIAL; GENOTYPE; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; LUNG DISEASES; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; SIGMA FACTOR; TRANS-ACTIVATORS;

EID: 79954716359     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02726.x     Document Type: Article

References (40)

1. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003;4:8.
2. Hoiby N. New insights into the pathogenesis and epidemiology of Pseudomonas aeruginosa infection in cystic fibrosis. In: H. Goossens, W. Peetermans and M. Struelens editors. Proceedings of the 4th Elzenveld Workshop on Infectious Diseases. Bristol-Meyers Squibb, Antwerpen, Belgium, 2005:11-19.
3. Johansen HK, Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992;47:109-11.
4. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 2002;34:232-6.
5. Jelsbak L, Johansen HK, Frost AL, Thogersen R, Thomsen LE, Ciofu O, et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun 2007;75:2214-24.
6. Martin C, Ichou MA, Massicot P, Goudeau A, Quentin R. Genetic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis revealed by restriction fragment length polymorphism of the rRNA gene region. J Clin Microbiol 1995;33:1461-6.
7. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006;103:8487-92.
8. Martin DW, Schurr MJ, Mudd MH, Govan JR, Holloway BW, Deretic V. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci USA 1993;90:8377-81.
9. Rau MH, Hansen SK, Johansen HK, Thomsen LE, Workman CT, Nielsen KF, et al. Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol 2010;12:1643-58.
10. Cabral DA, Loh BA, Speert DP. Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages. Pediatr Res 1987;22:429-31.
11. Meshulam T, Obedeanu N, Merzbach D, Sobel JD. Phagocytosis of mucoid and nonmucoid strains of Pseudomonas aeruginosa. Clin Immunol Immunopathol 1984;32:151-65.
12. Simpson JA, Smith SE, Dean RT. Scavenging by alginate of free radicals released by macrophages. Free Radic Biol Med 1989;6:347-53.
13. Pedersen SS, Kharazmi A, Espersen F, Hoiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun 1990;58:3363-8.
14. Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992;47:6-13.
15. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-74.
16. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009;44:547-58.
17. Ojeniyi B, Wolz C, Doring G, Lam JS, Rosdahl VT, Hoiby N. Typing of polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS 1990;98:423-31.
18. Bjarnsholt T, Jensen PO, Jakobsen TH, Phipps R, Nielsen AK, Rybtke MT, et al. Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS ONE 2010;5:e10115.
19. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Hoiby N. Genetic adaptation of P. aeruginosa during chronic lung infection: strong and weak mutators with heterogenous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 2010;156:1108-19.
20. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 1977;262:1-96.
21. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;28:159-66.
22. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505-16.
23. Ciofu O, Lee B, Johannesson M, Hermansen NO, Meyer P, Hoiby N. Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. Microbiology 2008;1:103-13.
24. Charlton TS, de NR, Netting A, Kumar N, Hentzer M, Givskov M, et al. A novel and sensitive method for the quantification of N-3-oxoacyl homoserine lactones using gas chromatography-mass spectrometry: application to a model bacterial biofilm. Environ Microbiol 2000;2:530-41.
25. Lee B, Haagensen JA, Ciofu O, Andersen JB, Hoiby N, Molin S. Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 2005;43:5247-55.
26. O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998;30:295-304.
27. Hsu F, Schwarz S, Mougous JD. TagR promotes PpkA-catalysed type VI secretion activation in Pseudomonas aeruginosa. Mol Microbiol 2009;72:1111-25.
28. Yang L, Haagensen JA, Jelsbak L, Johansen HK, Sternberg C, Hoiby N, et al. In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol 2008;190:2767-76.
29. Moser C, van GM, Bjarnsholt T, Jensen PO, Lee B, Hougen HP, et al. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS 2009;117:95-107.
30. Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008;190:7910-17.
31. Pesci EC, Pearson JP, Seed PC, Iglewski BH. Regulation of las and rhl quorum sensing in Pseudomonas aeruginosa. J Bacteriol 1997;179:3127-32.
32. Diggle SP, Winzer K, Chhabra SR, Worrall KE, Camara M, Williams P. The Pseudomonas aeruginosa quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol Microbiol 2003;50:29-43.
33. Dekimpe V, Deziel E. Revisiting the quorum-sensing hierarchy in Pseudomonas aeruginosa: the transcriptional regulator RhlR regulates LasR-specific factors. Microbiology 2009;155(Pt 3):712-23.
34. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-25.
35. Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip M, et al. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 2010;65:57-62.
36. Barth AL, Pitt TL. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. J Med Microbiol 1996;45:110-19.
37. Palmer KL, Mashburn LM, Singh PK, Whiteley M. Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 2005;187:5267-77.
38. Mougous JD, Cuff ME, Raunser S, Shen A, Zhou M, Gifford CA, et al. A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science 2006;312:1526-30.
39. Salunkhe P, Topfer T, Buer J, Tummler B. Genome-wide transcriptional profiling of the steady-state response of Pseudomonas aeruginosa to hydrogen peroxide. J Bacteriol 2005;187:2565-72.
40. Davey ME, Caiazza NC, O'Toole GA. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1. J Bacteriol 2003;185:1027-36.